Insulet Enrolls First Patients in Clinical Trial for its Omnipod® Artificial Pancreas
System
Study Brings Insulet Another Step Closer to Providing its Omnipod® Horizon™ Hybrid
Closed Loop System to People with Diabetes
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System),
today announced the first patient has completed the feasibility study of the Omnipod Horizon™ Automated Glucose Control System
(Omnipod Horizon System). The full study will evaluate the use of a personal Model Predictive Control algorithm with the Omnipod
platform in 20 adults with type 1 diabetes and is taking place in a clinical research center setting to gather data to be used to
evolve the algorithm in subsequent studies leading to FDA submission.
“We are very excited to be participating in Insulet’s artificial pancreas clinical trials,” said Jordan Pinsker, M.D., senior
research physician at William Sansum Diabetes Center. “Working with Professor Francis J. Doyle III and Dr. Eyal Dassau, Sansum
played a major role in the development of the original UC Santa Barbara Artificial Pancreas algorithm that Insulet acquired. We
look forward to contributing to the clinical and development pathway as Insulet takes this promising technology to a commercial
product.”
The Omnipod Horizon System will combine best-in-class technologies into one integrated system consisting of an on-body Omnipod
tubeless pump, the latest Dexcom continuous glucose monitoring (CGM) technology, a modified version of Insulet’s handheld
controller and state-of-the-art security system architecture. Insulet’s Omnipod Horizon System is unique in that the algorithm
looks toward the future horizon of blood glucose levels, reacting quickly and efficiently to adjust insulin delivery to optimize
outcomes for each user. The system will provide the same proven lifestyle benefits as the current Omnipod System, such as the
discreet, reliable, tubeless form factor and up to three days of non-stop insulin delivery to make it easy to stay connected and
avoid disruption of insulin delivery during routine activities like exercising and bathing.
“Our new Omnipod Horizon System is designed to deliver not only improved clinical outcomes, but the greatly desired improvement
in quality of life for those living with insulin-dependent diabetes,” said Patrick Sullivan, President and Chief Executive Officer.
“With the first clinical study of our innovative artificial pancreas underway, we have taken another important step in fulfilling
our mission to improve the lives of people with diabetes.”
Additional trial details, including enrollment information, can be found at ClinicalTrials.gov.
About the Omnipod Insulin Management System:
The Omnipod Insulin Management System is an innovative continuous insulin delivery system that provides all the proven benefits
of continuous subcutaneous insulin infusion (CSII) therapy in a way no conventional insulin pump can. The Omnipod System's
innovative design and features allows people living with diabetes to live their life—and manage their diabetes—with unprecedented
freedom, comfort, convenience, and ease. The Omnipod System consists of two components: (i) a Pod that stores and delivers
insulin; and (ii) a Personal Diabetes Manager (PDM) that wirelessly programs the user's personalized insulin delivery, calculates
suggested doses and insulin on board, and has a convenient, built-in blood glucose meter. The small, light-weight Pod can be worn
in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back and, because it is waterproof
(IPX8), there is no need to remove when showering, swimming or performing other activities. This means that Omnipod can provide up
to three days of non-stop insulin delivery, without the need to disconnect a tube set or manually inject insulin. The Pod and
PDM communicate wirelessly to offer precise, personalized and continuous insulin delivery with customizable basal and bolus
delivery options, as well as important safety checks. The Pod's auto-cannula insertion is quick, simple, and virtually pain-free.
Users never have to handle a needle. The user simply pushes a button on the PDM and the Pod's automated insertion system inserts
the cannula beneath the skin and begins delivering insulin according to the user's programmed basal rate.
The Omnipod System is the world's first commercially available tubeless insulin delivery system that allows users to live
untethered by tubing and without the stress and anxiety of multiple daily injections. By breaking down the barriers to insulin pump
therapy, the Omnipod System offers freedom for users to live life on their own terms and with the ease of use they deserve.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with
diabetes easier. Through its Omnipod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy
among people with insulin-dependent diabetes. The Omnipod is a revolutionary and easy-to-use tubeless insulin pump that features
just two parts and a fully-automated cannula insertion. Insulet's Delivery Systems business also partners with global
pharmaceutical and biotechnology companies to tailor the Omnipod technology platform for the delivery of subcutaneous drugs across
multiple therapeutic areas. To read inspiring stories of people with diabetes living their lives to the fullest with OmniPod,
please visit our customer blog, Suite D: http://suited.myomnipod.com. Founded in 2000, Insulet Corporation is based in Billerica,
Massachusetts. For more information, please visit: http://www.myomnipod.com.
Forward-Looking Statement:
This press release may contain forward-looking statements concerning Insulet's expectations, anticipations,
intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and
beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future
developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number
of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to
be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties
described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February
29, 2016 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and
Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove
incorrect, actual results may vary in material respects from those projected in these forward-looking
statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
Investor Relations and Media:
Insulet Corporation
Deborah R. Gordon, 978-600-7717
Vice President, Investor Relations and Corporate Communications
dgordon@insulet.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160913005517/en/